About Shukra Pharmaceuticals Limited
Data last updated: 14 July 2026
Shukra Pharmaceuticals Limited is a public limited company based in Ahmedabad, Gujarat, India. It specialises in drug formulation and development, a part of the broader pharmaceuticals sector. Incorporated on 04 March 1993, the company has been in operation for over 33 years.
Registered with ROC Ahmedabad under CIN L24231GJ1993PLC019079. Listed on BSE: 524632.
Capital: an authorised share capital of ₹49 Cr and a paid-up capital of ₹43.96 Cr. Formerly known as Relish Pharmaceuticals Private Limited and Relish Pharmaceuticals Limited. It is led by directors including Payal Sujay Mehta and Dakshesh Rameshchandra Shah.
Last AGM: 30 September 2025. Financial statements filed for year ended 31 March 2025. Office: Ahmedabad, Gujarat.
As per BSE-filed consolidated financials for FY 2026, the company reported a revenue of ₹56.73 Cr. The net worth stands at ₹89.85 Cr. Total assets are valued at ₹117.44 Cr.
The company has a workforce of approximately 56 employees as per the latest available data.
The company is associated with 1 brand - Shukrapharmaceuticals. As per MCA filings, the company has open charges of ₹14.33 Cr and satisfied charges of ₹21.92 Cr on record.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website shukrapharmaceuticals.com.
-
EmailLocked
-
TelephoneLocked
-
Website
-
Social MediaLocked
-
Registered Address3Rd Floor Dev House Opp. Wiaa Office Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, India – 380003
-
IndustryPharma, Drug Formulation & Development
- Historical Financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Litigation, compliance and MCA filings
- PDF report delivered after checkout
Name History of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has undergone 2 name changes throughout its history. The company was previously known as Relish Pharmaceuticals Private Limited, and Relish Pharmaceuticals Limited. The current legal name is Shukra Pharmaceuticals Limited, reflecting the company's evolution and rebranding over time.
| Company Name | Status |
|---|---|
| Shukra Pharmaceuticals Limited | Current |
| Relish Pharmaceuticals Private Limited | Previous |
| Relish Pharmaceuticals Limited | Previous |
CIN History of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has one previous CIN (Corporate Identification Number): U24231GJ1993PLC019079. The current CIN is L24231GJ1993PLC019079, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24231GJ1993PLC019079 | Current |
| U24231GJ1993PLC019079 | Previous |
Associated Brands with Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited operates one associated brand: Shukrapharmaceuticals. These brands represent Shukra Pharmaceuticals Limited's diversified market presence and brand portfolio.
| Brand | Description | Website |
|---|---|---|
| Affordable generic pharmaceuticals are manufactured and distributed globally. | shukrapharmaceuticals.com |
Business Activity of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited is engaged in principal business activities including manufacturing and trade, with detailed activities including chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products, wholesale trading. The company has 2 registered principal business activity segments, demonstrating its operational diversity and market reach.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products | Locked |
| G | Trade | G1 | Wholesale Trading | Locked |
Business activity turnover details for Shukra Pharmaceuticals Limited
Turnover contribution percentages and historical activity changes require an active report plan.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Auditor Details of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited is audited by MAAK and Associates for the financial year 2025. The auditor plays a crucial role in ensuring financial transparency and compliance with accounting standards.
| Name | Status | Appointment Date | Cessation Date |
|---|---|---|---|
| MAAK and Associates | Locked | Locked | Locked |
Complete auditor history for Shukra Pharmaceuticals Limited
Appointment status, appointment dates, cessation dates, and historical auditor changes require an active report plan.
- Appointment status
- Appointment dates
- Cessation dates
- Auditor changes
Verified entity values are shown only after access is granted.
Board of Directors of Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited is currently managed by 12 directors, with 20 former directors having served the organization. The current Directors play a crucial role in shaping the company's strategic direction and governance.
Financials of Shukra Pharmaceuticals Limited FY 2026 filings available
Shukra Pharmaceuticals Limited reported revenue of ₹56.73 Cr for FY 2026.
| Metrics | FY 2026 |
|---|---|
| Revenue from Operations | ₹56.73 Cr |
| Other Income | ₹4.58 Cr |
| Total Income | ₹61.31 Cr |
| Cost of Materials Consumed | ₹19.45 Cr |
| Purchases of Stock-in-Trade | ₹0 |
| Changes in Inventories | -₹3.6 Cr |
| Employee Benefit Expense | ₹7.04 Cr |
| Finance Costs | ₹1.09 Cr |
| Depreciation & Amortisation | ₹3.44 Cr |
| Other Expenses | ₹5.1 Cr |
| Total Expenses | ₹32.53 Cr |
| Profit Before Exceptional Items & Tax | ₹28.79 Cr |
| Exceptional Items | ₹0 |
| Profit Before Tax | ₹28.79 Cr |
| Total Tax Expense | ₹6.73 Cr |
| Net Profit | ₹22.06 Cr |
| Other Comprehensive Income | -₹8.72 Lakh |
| Total Comprehensive Income | ₹21.97 Cr |
| EBITDA (computed) | ₹33.32 Cr |
| Basic EPS | ₹0.50 |
| Diluted EPS | ₹0.50 |
| Metrics | FY 2026 |
|---|---|
| Total Assets | ₹117.44 Cr |
| Non-current Assets | ₹33.63 Cr |
| Current Assets | ₹83.81 Cr |
| Property, Plant & Equipment | ₹21.72 Cr |
| Inventories | ₹13.9 Cr |
| Trade Receivables | ₹22.95 Cr |
| Cash & Equivalents | ₹5.98 Cr |
| Equity (Net Worth) | ₹89.85 Cr |
| Equity Share Capital | ₹43.79 Cr |
| Borrowings (Non-current) | ₹3.19 Cr |
| Borrowings (Current) | ₹1.83 Cr |
| Total Debt (computed) | ₹5.02 Cr |
| Current Liabilities | ₹23.09 Cr |
| Total Liabilities | ₹27.59 Cr |
| Metrics | FY 2026 |
|---|---|
| Operating Cash Flow | ₹3.93 Cr |
| Investing Cash Flow | -₹14.14 Cr |
| Financing Cash Flow | ₹4.07 Cr |
| Capital Expenditure | ₹0 |
| Free Cash Flow (computed) | ₹3.93 Cr |
| Dividends Paid | ₹43.79 Lakh |
| Net Change in Cash | -₹6.14 Cr |
| Metrics | Q4 FY26 | Q3 FY26 |
|---|---|---|
| Revenue from Operations | ₹6.32 Cr | ₹39.13 Cr |
| Other Income | ₹94.72 Lakh | ₹81.54 Lakh |
| Total Income | ₹7.27 Cr | ₹39.95 Cr |
| Cost of Materials Consumed | ₹6.69 Cr | ₹3.2 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 |
| Changes in Inventories | -₹75 Lakh | ₹3.93 Cr |
| Employee Benefit Expense | ₹37.18 Lakh | ₹2.65 Cr |
| Finance Costs | ₹25.83 Lakh | ₹28.17 Lakh |
| Depreciation & Amortisation | ₹1.01 Cr | ₹83.87 Lakh |
| Other Expenses | -₹68.82 Lakh | ₹2.22 Cr |
| Total Expenses | ₹6.89 Cr | ₹13.12 Cr |
| Profit Before Exceptional Items & Tax | ₹38.16 Lakh | ₹26.83 Cr |
| Exceptional Items | ₹0 | ₹0 |
| Profit Before Tax | ₹38.16 Lakh | ₹26.83 Cr |
| Total Tax Expense | ₹2.1 Cr | ₹4.85 Cr |
| Net Profit | -₹1.72 Cr | ₹20.36 Cr |
| attributable to Owners | - | ₹0 |
| attributable to NCI | - | ₹0 |
| Other Comprehensive Income | -₹8.72 Lakh | ₹0 |
| Total Comprehensive Income | -₹1.8 Cr | ₹20.36 Cr |
| EBITDA (computed) | ₹1.65 Cr | ₹27.95 Cr |
| Basic EPS | ₹-0.04 | ₹0.47 |
| Diluted EPS | ₹-0.04 | ₹0.47 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical Segment | ₹7.25 Cr | ₹62.58 Lakh | ₹7.78 Lakh | ₹14.11 Cr |
| Medtech Segment | ₹0 | ₹0 | ₹11.55 Cr | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical Segment | ₹61.29 Cr | ₹29.87 Cr | - | - |
| Medtech Segment | ₹0 | ₹0 | - | - |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹56.71 Cr | ₹32.59 Cr | ₹74.57 Cr | ₹58.83 Cr | ₹20.49 Cr | ₹11.2 Cr | ₹11.85 Cr | ₹5.69 Cr |
| Other Income | ₹4.58 Cr | ₹4.21 Cr | ₹2.82 Cr | ₹1.2 Cr | ₹8.1 Lakh | ₹35.62 Lakh | ₹97,000 | ₹51,000 |
| Total Income | ₹61.29 Cr | ₹36.79 Cr | ₹77.39 Cr | ₹60.03 Cr | ₹20.57 Cr | ₹11.55 Cr | ₹11.86 Cr | ₹5.7 Cr |
| Cost of Materials Consumed | ₹19.45 Cr | ₹11.75 Cr | ₹13.38 Cr | ₹11.35 Cr | ₹11.08 Cr | ₹2.95 Cr | ₹3.33 Cr | ₹1.37 Cr |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹30.41 Cr | ₹34.3 Cr | ₹0 | ₹0 | ₹0 | ₹0 |
| Changes in Inventories | -₹3.6 Cr | -₹3.63 Cr | ₹70.15 Lakh | -₹33.38 Lakh | -₹73.41 Lakh | -₹19.26 Lakh | -₹25.9 Lakh | -₹15.96 Lakh |
| Employee Benefit Expense | ₹7.04 Cr | ₹6.11 Cr | ₹5.65 Cr | ₹4.89 Cr | ₹4.9 Cr | ₹4.07 Cr | ₹4.4 Cr | ₹1.96 Cr |
| Finance Costs | ₹1.09 Cr | ₹59.49 Lakh | ₹28.5 Lakh | ₹28.08 Lakh | ₹28.66 Lakh | ₹3.33 Lakh | ₹21,000 | ₹6,000 |
| Depreciation & Amortisation | ₹3.44 Cr | ₹3 Cr | ₹2.05 Cr | ₹1.84 Cr | ₹1.66 Cr | ₹1.47 Cr | ₹1.48 Cr | ₹96.26 Lakh |
| Other Expenses | ₹5.1 Cr | ₹5.64 Cr | ₹5.04 Cr | ₹3.26 Cr | ₹2.35 Cr | ₹2.93 Cr | ₹2.84 Cr | ₹77.26 Lakh |
| Total Expenses | ₹32.52 Cr | ₹23.46 Cr | ₹57.5 Cr | ₹55.59 Cr | ₹19.55 Cr | ₹11.26 Cr | ₹11.79 Cr | ₹4.91 Cr |
| Profit Before Exceptional Items & Tax | ₹28.77 Cr | ₹13.34 Cr | ₹19.88 Cr | ₹4.44 Cr | ₹1.02 Cr | ₹29.31 Lakh | ₹6.98 Lakh | ₹78.98 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | -₹19.53 Lakh | ₹10.1 Lakh | ₹0 |
| Profit Before Tax | ₹28.77 Cr | ₹13.34 Cr | ₹19.88 Cr | ₹4.44 Cr | ₹1.02 Cr | ₹9.78 Lakh | ₹17.08 Lakh | ₹78.98 Lakh |
| Total Tax Expense | ₹5.1 Cr | ₹3.76 Cr | ₹1.35 Cr | ₹3.52 Lakh | ₹26.73 Lakh | ₹6.4 Lakh | ₹13.52 Lakh | ₹32.71 Lakh |
| Net Profit | ₹22.05 Cr | ₹9.58 Cr | ₹18.54 Cr | ₹4.41 Cr | ₹75.07 Lakh | ₹3.38 Lakh | ₹3.56 Lakh | ₹46.27 Lakh |
| Other Comprehensive Income | -₹8.72 Lakh | ₹1.08 Lakh | ₹0 | -₹94,000 | ₹0 | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | ₹21.96 Cr | ₹9.59 Cr | ₹18.54 Cr | ₹4.4 Cr | ₹75.07 Lakh | ₹3.38 Lakh | ₹3.56 Lakh | ₹46.27 Lakh |
| EBITDA (computed) | ₹33.31 Cr | ₹16.94 Cr | ₹22.22 Cr | ₹6.56 Cr | ₹2.97 Cr | ₹1.8 Cr | ₹1.55 Cr | ₹1.75 Cr |
| Basic EPS | ₹0.50 | ₹0.22 | ₹16.93 | ₹26.21 | ₹4.79 | ₹0.22 | ₹0.23 | ₹2.96 |
| Diluted EPS | ₹0.50 | ₹0.22 | ₹16.93 | ₹26.21 | ₹4.79 | ₹0.22 | ₹0.23 | ₹2.96 |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | ₹117.41 Cr | ₹86.77 Cr | ₹77.84 Cr | ₹74.97 Cr | ₹35.11 Cr | ₹34.13 Cr | ₹33.53 Cr | ₹29.35 Cr |
| Non-current Assets | ₹33.66 Cr | ₹21.34 Cr | ₹48.43 Cr | ₹21.9 Cr | ₹19.45 Cr | ₹19.55 Cr | ₹19.09 Cr | ₹17.32 Cr |
| Current Assets | ₹83.75 Cr | ₹65.43 Cr | ₹29.41 Cr | ₹53.07 Cr | ₹15.67 Cr | ₹14.58 Cr | ₹14.43 Cr | ₹12.03 Cr |
| Property, Plant & Equipment | ₹21.72 Cr | ₹19.4 Cr | ₹19.94 Cr | ₹20.23 Cr | ₹17.58 Cr | ₹17.69 Cr | ₹17.38 Cr | ₹15.56 Cr |
| Inventories | ₹13.9 Cr | ₹9.95 Cr | ₹0 | ₹3.16 Cr | ₹3.95 Cr | ₹1.7 Cr | ₹1.32 Cr | ₹27.05 Lakh |
| Trade Receivables | ₹22.95 Cr | ₹8.77 Cr | ₹0 | ₹30.18 Cr | ₹7.4 Cr | ₹8.9 Cr | ₹7.95 Cr | ₹5.27 Cr |
| Cash & Equivalents | ₹5.92 Cr | ₹0 | ₹9.98 Cr | ₹3.97 Cr | ₹8.53 Lakh | ₹41.02 Lakh | ₹12.64 Lakh | ₹24.93 Lakh |
| Equity (Net Worth) | ₹89.83 Cr | ₹62.84 Cr | ₹57.64 Cr | ₹25.3 Cr | ₹16.35 Cr | ₹15.57 Cr | ₹15.41 Cr | ₹15.57 Cr |
| Equity Share Capital | ₹43.79 Cr | ₹43.79 Cr | ₹10.95 Cr | ₹3.91 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹1.57 Cr | ₹1.57 Cr |
| Borrowings (Non-current) | ₹3.19 Cr | ₹3.11 Cr | ₹2.66 Cr | ₹3.77 Cr | ₹3.13 Cr | ₹9.77 Cr | ₹8.05 Cr | ₹6.41 Cr |
| Borrowings (Current) | ₹1.83 Cr | ₹1.06 Cr | ₹49.72 Lakh | ₹1.31 Cr | ₹24.97 Lakh | ₹0 | ₹0 | ₹0 |
| Total Debt (computed) | ₹5.02 Cr | ₹4.18 Cr | ₹3.15 Cr | ₹5.08 Cr | ₹3.38 Cr | ₹9.77 Cr | ₹8.05 Cr | ₹6.41 Cr |
| Current Liabilities | ₹23.08 Cr | ₹17.28 Cr | ₹14.15 Cr | ₹42.51 Cr | ₹12.38 Cr | ₹5.69 Cr | ₹6.97 Cr | ₹4.4 Cr |
| Total Liabilities | ₹27.58 Cr | ₹23.93 Cr | ₹20.2 Cr | ₹49.67 Cr | ₹18.76 Cr | ₹18.56 Cr | ₹18.12 Cr | ₹13.78 Cr |
| Metrics | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
| Operating Cash Flow | ₹3.15 Cr | ₹7.92 Cr | -₹4.57 Cr | ₹3.17 Cr | ₹7.78 Cr |
| Investing Cash Flow | -₹14.18 Cr | -₹1.26 Cr | -₹1.83 Cr | -₹4.43 Cr | -₹1.53 Cr |
| Financing Cash Flow | ₹4.83 Cr | -₹4.52 Cr | ₹12.41 Cr | ₹4.94 Cr | -₹6.68 Cr |
| Capital Expenditure | ₹0 | ₹2.74 Cr | ₹1.76 Cr | ₹4.49 Cr | ₹1.55 Cr |
| Free Cash Flow (computed) | ₹3.15 Cr | ₹5.18 Cr | -₹6.33 Cr | -₹1.32 Cr | ₹6.23 Cr |
| Dividends Paid | ₹43.79 Lakh | ₹4.38 Cr | ₹7.02 Lakh | ₹7.28 Lakh | ₹0 |
| Net Change in Cash | -₹6.2 Cr | ₹2.14 Cr | ₹6.01 Cr | ₹3.68 Cr | -₹41.91 Lakh |
| Metrics | Q4 FY26 | Q3 FY26 | Q2 FY26 | Q1 FY26 | Q4 FY25 | Q3 FY25 | Q2 FY25 | Q1 FY25 |
|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | ₹6.3 Cr | ₹39.13 Cr | ₹5.88 Cr | ₹5.39 Cr | ₹13.27 Cr | ₹10.58 Cr | ₹5.56 Cr | ₹3.18 Cr |
| Other Income | ₹94.72 Lakh | ₹81.54 Lakh | ₹1.71 Cr | ₹1.11 Cr | ₹1.47 Cr | ₹1.01 Cr | ₹1.02 Cr | ₹71.76 Lakh |
| Total Income | ₹7.25 Cr | ₹39.95 Cr | ₹7.59 Cr | ₹6.5 Cr | ₹14.74 Cr | ₹11.59 Cr | ₹6.57 Cr | ₹3.9 Cr |
| Cost of Materials Consumed | ₹6.69 Cr | ₹3.2 Cr | ₹10.81 Cr | -₹1.25 Cr | ₹5.59 Cr | ₹3.78 Cr | ₹1.45 Cr | ₹92.15 Lakh |
| Purchases of Stock-in-Trade | ₹0 | ₹0 | ₹0 | ₹2.02 Cr | ₹0 | ₹0 | ₹86.28 Lakh | ₹0 |
| Changes in Inventories | -₹75 Lakh | ₹3.93 Cr | -₹8.8 Cr | ₹0 | -₹3.83 Cr | ₹17.5 Lakh | ₹6.35 Lakh | -₹90.48 Lakh |
| Employee Benefit Expense | ₹37.18 Lakh | ₹2.65 Cr | ₹2.19 Cr | ₹1.82 Cr | ₹1.75 Cr | ₹1.55 Cr | ₹1.43 Cr | ₹1.38 Cr |
| Finance Costs | ₹25.83 Lakh | ₹28.17 Lakh | ₹28.5 Lakh | ₹26.81 Lakh | ₹27.08 Lakh | ₹15.13 Lakh | ₹11.11 Lakh | ₹6.17 Lakh |
| Depreciation & Amortisation | ₹1.01 Cr | ₹83.87 Lakh | ₹80.92 Lakh | ₹78.72 Lakh | ₹94.39 Lakh | ₹69.78 Lakh | ₹69.82 Lakh | ₹66.51 Lakh |
| Other Expenses | -₹69.53 Lakh | ₹2.22 Cr | ₹2.1 Cr | ₹1.48 Cr | ₹2.44 Cr | ₹1.14 Cr | ₹1.08 Cr | ₹97.27 Lakh |
| Total Expenses | ₹6.88 Cr | ₹13.12 Cr | ₹7.39 Cr | ₹5.13 Cr | ₹7.16 Cr | ₹7.5 Cr | ₹5.7 Cr | ₹3.1 Cr |
| Profit Before Exceptional Items & Tax | ₹36.75 Lakh | ₹26.83 Cr | ₹19.85 Lakh | ₹1.37 Cr | ₹7.57 Cr | ₹4.09 Cr | ₹87.49 Lakh | ₹79.67 Lakh |
| Exceptional Items | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 | ₹0 |
| Profit Before Tax | ₹36.75 Lakh | ₹26.83 Cr | ₹19.85 Lakh | ₹1.37 Cr | ₹7.57 Cr | ₹4.09 Cr | ₹87.49 Lakh | ₹79.67 Lakh |
| Total Tax Expense | ₹2.09 Cr | ₹4.85 Cr | -₹2.18 Cr | ₹34.34 Lakh | ₹2.18 Cr | ₹93.05 Lakh | ₹33.6 Lakh | ₹31.14 Lakh |
| Net Profit | -₹1.73 Cr | ₹20.36 Cr | ₹2.38 Cr | ₹1.03 Cr | ₹5.39 Cr | ₹3.16 Cr | ₹53.89 Lakh | ₹48.53 Lakh |
| Other Comprehensive Income | -₹8.72 Lakh | ₹0 | ₹0 | ₹0 | ₹1.08 Lakh | ₹0 | ₹0 | ₹0 |
| Total Comprehensive Income | -₹1.81 Cr | ₹20.36 Cr | ₹2.38 Cr | ₹1.03 Cr | ₹5.4 Cr | ₹3.16 Cr | ₹53.89 Lakh | ₹48.53 Lakh |
| EBITDA (computed) | ₹1.63 Cr | ₹27.95 Cr | ₹1.29 Cr | ₹2.43 Cr | ₹8.78 Cr | ₹4.94 Cr | ₹1.68 Cr | ₹1.52 Cr |
| Basic EPS | ₹-0.04 | ₹0.47 | ₹0.05 | ₹0.02 | ₹0.12 | ₹0.72 | ₹0.25 | ₹0.11 |
| Diluted EPS | ₹-0.04 | ₹0.47 | ₹0.05 | ₹0.02 | ₹0.12 | ₹0.72 | ₹0.25 | ₹0.11 |
| Segment · Q4 FY26 (latest quarter) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical Segment | ₹7.25 Cr | ₹62.58 Lakh | ₹7.78 Lakh | ₹14.11 Cr |
| Medtech Segment | ₹0 | ₹0 | ₹11.55 Cr | ₹0 |
| Segment · FY 2026 (annual) | Revenue | Result (PBIT) | Assets | Liabilities |
|---|---|---|---|---|
| Pharmaceutical Segment | ₹61.29 Cr | ₹29.87 Cr | - | - |
| Medtech Segment | ₹0 | ₹0 | - | - |
Shareholding Pattern of Shukra Pharmaceuticals Limited
As per the shareholding pattern filed with BSE for the quarter ended Mar 2026, promoters hold 50.96%, domestic institutional investors hold 0.11%, retail and other public shareholders hold 48.93% of Shukra Pharmaceuticals Limited. The company had 27,173 shareholders on record.
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|
| Promoters | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% | 50.96% |
| Public | 49.04% | 49.04% | 49.04% | 49.04% | 49.04% | 49.04% |
| Mar 2026 | Mar 2025 | Mar 2024 | |
|---|---|---|---|
| Promoters | 50.96% | 50.96% | 50.96% |
| Public | 49.04% | 49.04% | 49.04% |
| Promoter change (YoY, %pts) | +0.00 | +0.00 | - |
Charges & Borrowings of Shukra Pharmaceuticals Limited
| Date | Lender | Amount | Status |
|---|---|---|---|
| 17 Apr 2026 | Others | ₹9.9 Cr | Open |
| 11 Mar 2026 | Others | ₹1.6 Cr | Open |
| 24 Aug 2025 | Others | ₹28.89 Lakh | Open |
| 06 Aug 2025 | Others | ₹28.8 Lakh | Open |
| 16 Dec 2022 | Tata Capital Financial Services Limited | ₹75 Lakh | Open |
Total charge records: 19 View all charges
Employees and EPFO Compliance at Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited has a workforce of 56 employees as of Jan 24, 2026.
Employee and EPFO history for Shukra Pharmaceuticals Limited
Monthly headcount, contribution history, establishment records, and filing compliance require an active report plan.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
GST Compliance of Shukra Pharmaceuticals Limited
GST registrations and filing compliance for Shukra Pharmaceuticals Limited
State-wise registrations, return filing status, HSN and SAC details, and jurisdiction records require an active report plan.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
Credit Ratings, Litigation & Regulatory Alerts for Shukra Pharmaceuticals Limited
Credit ratings, litigation, and regulatory alerts for Shukra Pharmaceuticals Limited
Agency ratings, court records, regulatory events, and entity-specific compliance alerts require an active report plan.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Shukra Pharmaceuticals Limited
MSME payment history for Shukra Pharmaceuticals Limited
Amounts outstanding to micro and small suppliers, delay reasons, and MSME-1 filing history require an active report plan.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Shukra Pharmaceuticals Limited
Corporate group structure for Shukra Pharmaceuticals Limited
Parent, subsidiary, associate, joint venture, and ownership records require an active report plan.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Shukra Pharmaceuticals Limited
MCA filings and documents for Shukra Pharmaceuticals Limited
Official forms, annual returns, financial statements, charge filings, and document dates require an active report plan.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Recent Activity on Shukra Pharmaceuticals Limited
Frequently Asked Questions about Shukra Pharmaceuticals Limited
Shukra Pharmaceuticals Limited is an active public limited company in the pharma sector based in Ahmedabad, Gujarat, India. It was incorporated on 04 March 1993 (33+ years old) and is registered under CIN L24231GJ1993PLC019079. Listed on BSE: 524632. The company has 56 employees.
Shukra Pharmaceuticals Limited reported revenue of ₹56.73 Cr for FY 2026 based on consolidated BSE filings.
The current directors of Shukra Pharmaceuticals Limited are:
- Payal Sujay Mehta - Director
- Dakshesh Rameshchandra Shah - Managing Director
- Dinesh Chauhan - Additional Director
- Shital Shah - Whole-Time Director
- Ritu Kapoor - Director
- Anar Jayeshbhai Patel - Whole-Time Director
- Jitendra Somchand Shah - Director
- Pinki Nirmal Sagar - Director
- Sonal Deepalbhai Gandhi - Director
- Sanskruti Jayeshbhai Patel - Whole-Time Director
- Sarjeevan Singh - Director
- Dhruvin Shah - Whole-Time Director
The primary industry of Shukra Pharmaceuticals Limited is pharma. The company specifically operates in drug formulation and development. The company is currently active in this sector.
Yes. Shukra Pharmaceuticals Limited is listed on BSE with code 524632.
Shukra Pharmaceuticals Limited can be reached at the registered office: 3Rd Floor Dev House Opp. Wiaa Office Judges Bungalows Road, Bodakdev, Ahmedabad, Gujarat, India – 380003, or through the website shukrapharmaceuticals.com.